-
Apimeds (APUS) halted, news pending
-
Apimeds merges with MindWave in biotech-digital asset deal
-
Apimeds partners with University of Alabama for biotech program
-
Apimeds adds two executives to leadership team
-
D. Boral Capital Acted as Sole Bookrunner to Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) in connection with its $13.5 Million Initial Public Offering
-
Apimeds Pharmaceuticals US (APUS) Files for 3.33M Share IPO at $3-$4/sh

